Adbiotech애드바이오텍
179530 · KOSDAQ · ₩179530 · 애드바이오텍
₩1,909▼ ₩74 (3.73%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 40.5% | 39.9% | 36.0% | 30.7% | 29.3% | 42.3% |
| Operating margin | −35.1% | −27.1% | −37.0% | −45.5% | −46.4% | −13.1% |
| Net margin | −28.1% | −25.6% | −71.4% | −27.3% | 25.4% | −22.5% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −2.5% | +15.8% | +6.3% | −1.5% | −10.2% | — |
| Operating income growth | −26.0% | +15.0% | +13.5% | +3.6% | −217.7% | — |
| Net income growth | −6.8% | +58.5% | −177.7% | −206.2% | +201.2% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −16.2% | −32.8% | −87.2% | −19.4% | 25.3% | −52.2% |
| Return on assets | 2.4% | −9.3% | −35.1% | −18.4% | 10.4% | −12.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 103.8% | 257.5% | 675.6% | 159.0% | 91.6% | 310.5% |
| Net debt to equity | −1.9% | 43.7% | 351.2% | 39.4% | 71.3% | 233.2% |
| Current ratio | 108.5% | 66.2% | 54.8% | 103.3% | 119.8% | 68.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Adbiotech / 애드바이오텍 / 179530 / KRX:179530
Source: KRX statistical information